Company intelligence / Profile preview
STORM Therapeutics
Cambridge, England, UKstormtherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The first company to advance an RNA modifying enzyme inhibitor (STC-15) into clinical trials Dosed first patient in Phase I trial for solid tumors in November 2022 (NCT05584111) Preclinical data shows immune activation and tumor growth inhibition through METTL3 inhibition
- Therapeutic areas
- OncologyImmunologyNeurologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Evotec AG
Beyond the preview
Go deeper on STORM Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STORM Therapeutics.